Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 10:00:23 pm
37.2 USD   +2.03%
04:34p DOW MOVERS : Ibm, pfe
02:04p PFIZER INC. : Announces Expiration and Results of its Private Exchan..
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Reports from Pfizer Describe Recent Advances in Hormones (Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2017 | 11:52pm CET

Reports from Pfizer Describe Recent Advances in Hormones (Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Hormones have been published. According to news originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, "To examine the role that enzyme Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT1) plays in postprandial gut peptide secretion and signaling. The standard experimental paradigm utilized to evaluate the incretin response was a lipid challenge."

Our news journalists obtained a quote from the research from Pfizer, "Following a lipid challenge, plasma was collected cardiac puncture at each time point from a cohort of 5-8 mice per group from baseline at time zero to 10 h. Incretin hormones [glucagon like peptide-1 (GLP-1), peptide tyrosine-tyrosine (PYY) and glucose dependent insulinotropic polypeptide (GIP)] were then quantitated. The impact of pharmacological inhibition of DGAT1 on the incretin effect was evaluated in WT mice. Additionally, a comparison of loss of DGAT1 function either by genetic ablation or pharmacological inhibition. To further elucidate the pathways and mechanisms involved in the incretin response to DGAT1 inhibition, other interventions [inhibitors of dipeptidyl peptidase-IV (sitagliptin), pancreatic lipase (Orlistat), GPR119 knockout mice] were evaluated. DGAT1 deficient mice and wildtype C57/BL6J mice were lipid challenged and levels of both active and total GLP-1 in the plasma were increased. This response was further augmented with DGAT1 inhibitor PF-04620110 treated wildtype mice. Furthermore, PF-04620110 was able to dose responsively increase GLP-1 and PYY, but blunt GIP at all doses of PF-04620110 during lipid challenge. Combination treatment of PF-04620110 and Sitagliptin in wildtype mice during a lipid challenge synergistically enhanced postprandial levels of active GLP-1. In contrast, in a combination study with Orlistat, the ability of PF-04620110 to elicit an enhanced incretin response was abrogated. To further explore this observation, GPR119 knockout mice were evaluated. In response to a lipid challenge, GPR119 knockout mice exhibited no increase in active or total GLP-1 and PYY. However, PF-04620110 was able to increase total GLP-1 and PYY in GPR119 knockout mice as compared to vehicle treated wildtype mice."

According to the news editors, the research concluded: "Collectively, these data provide some insight into the mechanism by which inhibition of DGAT1 enhances intestinal hormone release."

For more information on this research see: Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion. World Journal of Gastrointestinal Pathophysiology, 2017;8(4):161-175 (see also Drugs and Therapies - Hormones).

The news correspondents report that additional information may be obtained from B.S. Maciejewski, Pfizer Worldwide Research and Development, Cardiovascular and Metabolic Diseases Research Unit, Cambridge, MA 02139, United States. Additional authors for this research include T.B. Manion and C.M Steppan.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.4291/wjgp.v8.i4.161. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Hormones, Peptides, Proteins, Cambridge, Incretins, Proteomics, Pharmacology, Massachusetts, United States, Acyltransferases, Drugs and Therapies, Enzymes and Coenzymes, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:34p DOW MOVERS : Ibm, pfe
02:04p PFIZER INC. : Announces Expiration and Results of its Private Exchange Offer for..
01:26p PFIZER : Kirsten Lund-Jurgensen Named to Executive Committee of Manufacturers As..
11:34a PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofa..
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
11:19a PFIZER : `No plans to launch second approved Remicade biosimilar in US`
10:29a PFIZER : Fda approves new pfizer biosimilar
10:29a PFIZER : Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Sh..
10:29a PFIZER : Phase 3 trumenba data published in new england journal of medicine demo..
10:11a PFIZER INC. (LON : PFZ) Files An 8-K Financial Statements and Exhibits
More news
News from SeekingAlpha
06:56a FDA OKs Pfizer's Xeljanz for psoriatic arthritis; shares up 1% premarket
02:24a PFIZER : Strong Cash Flow, Improving Pipeline, And A Dividend Hike Coming Up
12/14 Test Portfolio Results And Introducing A New Quality Portfolio
12/14 Pfizer launches Phase 3 program for JAK1 inhibitor PF-04965842 in atopic derm..
12/14 More Positives For Roche, The Core Biotech For The Long Run
Financials ($)
Sales 2017 52 550 M
EBIT 2017 19 881 M
Net income 2017 10 958 M
Debt 2017 23 944 M
Yield 2017 3,50%
P/E ratio 2017 19,55
P/E ratio 2018 16,86
EV / Sales 2017 4,59x
EV / Sales 2018 4,46x
Capitalization 217 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 38,2 $
Spread / Average Target 4,9%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER12.81%217 327
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976